Phase 1 Atrial Fibrillation Trial, Recruiting NCT03830320 Sponsor: Massachusetts General Hospital Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 1 Atrial Fibrillation Trial, Recruiting

NCT03830320
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you have Atrial Fibrillation (an irregular heartbeat condition):

  • You have a history of atrial fibrillation (irregular heartbeat), including the type that comes and goes
  • You have recently had (within the last 14 days) a special heart ultrasound called a TEE to look at a part of your heart, and your blood-thinning medication has not been changed since then
  • Or, you are scheduled to have that heart ultrasound (TEE) within the next 14 days

If you have had COVID-19:

  • You tested positive for COVID-19 using a standard lab test within the last month
  • You do not need a breathing machine (ventilator) to help you breathe

If you have cancer:

  • You have been diagnosed with cancer

If you have another condition involving blood clots:

  • A scan (ultrasound or CT) has confirmed, or strongly suggests, that you have a blood clot (for example, based on a blood test result)
  • You have not received clot-dissolving medications

Who may not be able to join:

  • Anyone under 18 years of age
  • Anyone who has an electrical device implanted in their body, such as a pacemaker
  • Anyone who is pregnant or breastfeeding (a pregnancy blood test will be required for women who could potentially be pregnant)
  • Anyone who experiences severe anxiety in enclosed spaces (claustrophobia)
  • Anyone whose radiation exposure from research studies in the past 12 months has already reached the maximum safe level allowed
  • Anyone who cannot lie still and comfortably on a flat scanner bed
  • Anyone who is directly or indirectly supervised by the lead researchers running this trial
  • Anyone whose body weight exceeds the weight limits of the scanning equipment (over 300 lbs for the MRI table or over 441 lbs for the CT table)
  • Anyone with metal or electrical implants in their body that are not safe to use with the type of scanner being used in this study (confirm with trial site)
  • Anyone who is not able to give their own written consent to participate
  • Anyone the research team decides is not medically suitable for the study, based on their assessment

Additional reasons someone with Atrial Fibrillation may not be able to join:

  • You have had a stroke within the last 3 months
  • You have had a heart attack within the last 3 months
  • You have had heart surgery or another major surgery within the last 3 months
  • You have had chest pain in the last 6 weeks, unless you have since had a stress test or heart artery scan to investigate it
  • You have fainted or blacked out in the last 6 weeks
  • Your heart rate is consistently too fast (above 120 beats per minute) or too slow (below 50 beats per minute)
  • You experience pauses in your heartbeat during the day that last longer than 3 seconds

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ciprian Catana, PhD, Massachusetts General Hospital

Phone: 617-724-3407

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
1 April 2016
Est. completion
31 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Complete blood count; Target to Background Ratio LAA; Target to Background Ratio; Time activity curve

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov